Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680158 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
A NA study, sponsored by Oculeve.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT02680158 is a NA study that has completed, run by Oculeve. The registered enrollment target is 48 participants.
The verdict
NCT02680158, a NA study, has completed, sponsored by Oculeve.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
Interventions
- DEVICE Sham
- DEVICE Oculeve Intranasal
- DEVICE Oculeve Extranasal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-01-31 |
| Est. Completion | 2016-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680158
The ClinicalTrials.gov registry entry for NCT02680158 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculeve, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT02680158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02680158 about?
NCT02680158 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome". The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
What is the current status of trial NCT02680158?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2016-01-31. Estimated completion is 2016-03-31.
What interventions are being tested in trial NCT02680158?
The interventions under investigation include: Sham (DEVICE), Oculeve Intranasal (DEVICE), Oculeve Extranasal (DEVICE).
Who is sponsoring clinical trial NCT02680158?
This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.